Egypt Approves Quadrivalent Flu Shot for 2023

GC Biopharma recently announced that its flu vaccine GC FLU Quadrivalent Pre-filled syringe Intramuscular was approved by the Egyptian Drug Authority (EDA).

As of July 18, 2023, this is the first approval the South Korea-based company had obtained for its flu vaccine from the Arab Republic of Egypt on the African continent. Egypt has one of the largest pharmaceutical markets in the African region.

Taking this EDA approval as an opportunity, GC Biopharma plans to expand its global presence further, which has been centering on Southeast Asia and Latin American regions to Africa and the Middle East.

Based on GC Biopharma's internationally recognized seasonal flu vaccine production technology, GC FLU has been expanding its export volume and number of markets yearly.

At the same time, the company will push ahead with entering into the private markets of individual countries based on its successful presence in the procurement markets of international organizations.

"The trend of moving away to quadrivalent flu vaccines is clear not only in the procurement market led by international organizations but also in the individual private markets," points out GC Biopharma in a press release on July 21, 2023, and further emphasizes, "We will target both international organizations' procurement markets as well as the private markets to draw synergy and boost our sales and profitability."

According to the company, the flu vaccine market divides into two parts: the procurement market of international organizations represented by the PAHO of WHO and the UNICEF; and the private markets of each country that supplies pharmaceuticals based on the approvals of respective authorities.

The WHO prequalified the GC FLU vaccine in 2016. There are nine manufacturers of WHO-prequalified influenza vaccines in 2023.